Journal
ALZHEIMERS & DEMENTIA
Volume 10, Issue 1, Pages 53-61Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2012.12.006
Keywords
Alzheimer's disease; Amyloid-beta; Biomarkers; Diagnosis; Pittsburgh compound B; Positron emission tomography
Categories
Funding
- CSIRO
- Science Industry and Endowment Fund
- National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DCRC2)
- Victorian government
- Pfizer International
- Innogenetics-Fujirebio (Ghent, Belgium)
Ask authors/readers for more resources
Background: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). Methods: Plasma amyloid beta (A beta)(1-40), A beta(1-42), A beta(n-40), and A beta(n-42) peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. A beta peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. Results: Although inflammatory and renal function covariates influenced plasma A beta levels significantly, a decrease in A beta(1-42)/A beta(1-40) was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma A beta(1-42) decreased in subjects with mild cognitive impairment (MCI) and in those transitioning from healthy to MCI. Conclusion: Our findings are consistent with a number of published plasma A beta studies and, although the prognostic value of individual measures in any given subject is limited, the diagnostic contribution of plasma A beta may demonstrate utility when combined with a panel of peripheral biomarkers. (C) 2014 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available